Study on Midostaurin and Decitabine for Adults with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Who Are Unfit for Intensive Treatment

2 1 1 1

What is this study about?

This clinical trial is focused on studying two blood-related diseases: Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). These are conditions where the bone marrow does not produce enough healthy blood cells. The study is testing a treatment that combines two medications: Midostaurin and Decitabine. Midostaurin is taken as a soft capsule, while Decitabine is given as an infusion, which means it is delivered directly into the bloodstream through a vein.

The purpose of the study is to see how well the combination of Midostaurin and Decitabine works in treating patients who are not fit for standard chemotherapy. The study will compare the effects of adding Midostaurin to a 10-day treatment with Decitabine. Participants will receive this treatment over three cycles, and the study will look at how many patients achieve a complete response, which means no signs of the disease are found after treatment.

During the study, researchers will also monitor the safety and tolerability of the treatment, which means they will check for any side effects and how severe they are. The study will also look at how long patients live without the disease getting worse and their overall survival. Additionally, the study will explore if certain gene mutations can predict how well patients respond to the treatment. The study is expected to continue until December 2026.

1 initial assessment

Upon joining the clinical trial, an initial assessment is conducted to confirm eligibility. This includes reviewing medical history and performing necessary tests to ensure the patient meets the criteria for participation.

2 treatment cycle 1

The first treatment cycle begins with the administration of decitabine. This medication is given as an infusion into a vein, known as intravenous use, over a period of 10 days.

Following the decitabine treatment, midostaurin is taken orally. The dosage is 25 mg in the form of soft capsules, taken twice daily.

3 monitoring and evaluation

Throughout the treatment cycle, regular monitoring is conducted to assess the patient’s response to the medications. This includes blood tests and other evaluations to track progress and identify any side effects.

4 treatment cycle 2

The second treatment cycle follows the same procedure as the first. Decitabine is administered intravenously for 10 days, followed by oral midostaurin at a dosage of 25 mg twice daily.

5 further monitoring

After the second cycle, additional monitoring is performed to evaluate the effectiveness of the treatment and to check for any adverse effects.

6 treatment cycle 3

The third treatment cycle is conducted in the same manner as the previous cycles, with decitabine given intravenously for 10 days and midostaurin taken orally at 25 mg twice daily.

7 final evaluation

At the end of the third cycle, a comprehensive evaluation is performed to determine the overall response to the treatment. This includes assessing the cumulative complete response rate and any remaining symptoms.

Who Can Join the Study?

Must have a diagnosis of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with excess blasts, according to the WHO 2016 classification. This does not include acute promyelocytic leukemia.
Must be 18 years or older.
Must not be eligible for standard chemotherapy. This means either having a high score (HCT-CI ≥ 3) indicating other health issues or choosing not to undergo standard chemotherapy for personal reasons.
Must have a white blood cell (WBC) count of ≤ 30 x 10⁹/L. If hydroxyurea was used to lower WBC, it should be stopped 2 days before starting decitabine treatment.
Must have adequate kidney and liver function, unless the disease affects these organs. This is shown by specific lab values:
- Serum creatinine ≤ 221.7 µmol/L (≤ 2.5 mg/dL), unless related to AML.
- Serum bilirubin ≤ 2.5 times the upper limit of normal, unless related to AML or due to Gilbert’s syndrome.
- Alanine transaminase (ALT) ≤ 2.5 times the upper limit of normal, unless related to AML.
Must have a WHO performance status of 0, 1, or 2, which indicates the level of daily activity a person can perform.
Must be willing and able to use adequate contraception during the study and for 5 months after the last treatment.
Must provide written informed consent, meaning they understand the study and agree to participate.
Must be capable of giving informed consent, meaning they can understand the information and make decisions about their participation.

Who Cannot Join the Study?

Patients with other types of cancer that are not acute myeloid leukemia or myelodysplastic syndrome cannot participate.
Patients who have had a heart attack or severe heart problems in the past 6 months are not eligible.
Patients with uncontrolled high blood pressure cannot join the study.
Patients who are pregnant or breastfeeding are not allowed to participate.
Patients with severe liver or kidney disease cannot take part in the trial.
Patients who have an active infection that requires treatment with antibiotics are excluded.
Patients who have received another investigational drug within the last 30 days cannot participate.
Patients with a known allergy to the study drug or similar drugs are not eligible.
Patients who are unable to comply with the study procedures and follow-up visits are excluded.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Stichting OLVG	Amsterdam	The Netherlands
Frisius	Heerenveen	The Netherlands
University Hospital Maastricht	Maastricht	The Netherlands

Other Sites

Site Name	City	Country
Ziekenhuis Gelderse Vallei Stichting	Ede	The Netherlands
Haga Hospital	Hague	The Netherlands
Isala Klinieken Stichting	Zwolle	The Netherlands
Jeroen Bosch Ziekenhuis Stichting	s-Hertogenbosch	The Netherlands
Canisius Wilhelmina Ziekenhuis	Nijmegen	The Netherlands
Amphia Hospital	Breda	The Netherlands
Algemeen Ziekenhuis Delta	Roeselare	Belgium
Albert Schweitzer Ziekenhuis	Dordrecht	The Netherlands
Medisch Spectrum Twente	Enschede	The Netherlands
Maxima Medisch Centrum	Veldhoven	The Netherlands
Universitair Medisch Centrum Utrecht	Utrecht	The Netherlands
Catharina Ziekenhuis Stichting	Eindhoven	The Netherlands
St. Antonius Ziekenhuis	Nieuwegein	The Netherlands
Meander Medical Center	Amersfoort	The Netherlands
Gasthuiszusters Antwerpen	Antwerp	Belgium
Reinier de Graaf Groep	Delft	The Netherlands
Slingeland Ziekenhuis	Doetinchem	The Netherlands
Rsxbioexs Zbausgubka Sqrgdhlrm	Arnhem	The Netherlands
Unjgbuyatmuk Mkmmgte Crwbzwk Gwqrczehj	Groningen	The Netherlands
Hhkmwfy Jlbsxkhx	Haine-Saint-Paul	Belgium
Agvbqbqzw Uzg	Amsterdam	The Netherlands
Ehjdjli Uyepgkooxutm Mhmqfzh Cmxvxte Rpmoubytu (pkbdhud Mou	Rotterdam	The Netherlands

Trial status

Country	Status	Recruitment Start
Belgium	Not recruiting	01.12.2019
The Netherlands	Not recruiting	01.12.2019

Trial locations

Investigated drugs:

Midostaurin is a medication used in this clinical trial to help treat certain types of blood cancers, such as acute myeloid leukemia (AML) and high-risk myelodysplasia (MDS). It works by blocking specific proteins that cancer cells need to grow, which may help slow down or stop the cancer from spreading. In this study, midostaurin is being tested to see if it can improve the effectiveness of another treatment when used together.

Decitabine is another medication used in this trial. It is a type of chemotherapy that helps to stop the growth of cancer cells by interfering with their DNA. Decitabine is used to treat blood cancers like AML and MDS, and in this study, it is given over a period of 10 days. The trial is investigating whether adding midostaurin to decitabine can improve treatment outcomes for patients who are not fit for more intensive therapies.

Investigated diseases:

Myelodysplastic syndrome

Acute myeloid leukemia – Acute myeloid leukemia is a type of cancer that starts in the blood-forming cells of the bone marrow. It progresses rapidly, leading to the accumulation of immature white blood cells called myeloblasts. These cells crowd out normal blood cells, causing symptoms like fatigue, frequent infections, and easy bruising or bleeding. As the disease advances, it can spread to other parts of the body, including the lymph nodes, liver, and spleen. The rapid progression requires prompt medical attention to manage symptoms and complications.

Myelodysplastic syndrome – Myelodysplastic syndrome is a group of disorders caused by poorly formed or dysfunctional blood cells. It begins in the bone marrow, where blood cells are produced, leading to a shortage of healthy blood cells. This can result in symptoms such as fatigue, shortness of breath, and increased risk of bleeding and infections. Over time, the condition can worsen, with a potential to transform into acute myeloid leukemia. The progression varies among individuals, with some experiencing a slow course while others may have a more rapid decline in blood cell production.

Trial ID:

2023-503829-18-00

Protocol code:

HO155

NCT ID:

NCT04097470

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Midostaurin and Decitabine for Adults with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Who Are Unfit for Intensive Treatment

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?